Protalix BioTherapeutics (PLX) Depreciation and Depletion (2015 - 2026)

Protalix BioTherapeutics' Depreciation and Depletion history runs 12 years deep, the most recent figure standing at $404000.0 for Q1 2026.

• In Q1 2026, Depreciation and Depletion rose 16.76% year-over-year to $404000.0; the TTM figure through Mar 2026 stood at $1.5 million (up 14.68% YoY), while the FY2025 annual figure was $1.5 million, up 12.35% from the prior year.
• Depreciation and Depletion was $404000.0 for Q1 2026 at Protalix BioTherapeutics, up from $387000.0 in the prior quarter.
• In the past five years, Depreciation and Depletion ranged from a high of $404000.0 in Q1 2026 to a low of $268000.0 in Q2 2022.
• Historically, Depreciation and Depletion has averaged $321411.8 across 5 years, with a median of $319000.0 in 2024.
• The sharpest annual moves came in 2022 and 2026: Depreciation and Depletion fell 6.94% in 2022, then grew 16.76% in 2026.
• A 5-year view of Depreciation and Depletion shows it stood at $289000.0 in 2022, then advanced by 8.3% to $313000.0 in 2023, then gained by 6.71% to $334000.0 in 2024, then advanced by 15.87% to $387000.0 in 2025, then grew by 4.39% to $404000.0 in 2026.
• The last three Depreciation and Depletion figures came in at $404000.0 (Q1 2026), $387000.0 (Q4 2025), and $372000.0 (Q3 2025), per Business Quant data.